



AMR TECHNICAL SCORECARD

HUMAN

Bacterial Culture, Detection,
Identification and Antimicrobial
Susceptibility Testing of Wound
Samples

Wound

Version 1.0 - August 2021





Score

Section	Sum of	Curren	t Audit	Previous audit	
	maximum	Date:		Date:	
	points ²	Currer	nt audit	Previou	ıs audit
		sc	ore	sc	ore
1. Documents and Records			%		%
2. Management Reviews			%		%
3. Organization and Personnel			%		%
4. Client Management and Customer Service			%		%
5. Equipment			%		%
6. Evaluation and Audits			%		%
7. Purchasing and Inventory			%		%
8. Process Control and Internal and External Quality Assessment			%		%
9. Information Management			%		%
10. Corrective Action			%		%
11. Occurrence Management and Process Improvement			%		%
12. Facilities and Safety			%		%
Wound Module Total			%		%
Wound Module Stars ³					

 $^{^{\}rm 2}\,\text{Total}$ number of points of all questions minus points for questions answered with NA.

³ No Stars < 55%

¹ Star 55% - 64%

² Stars 65% - 74%

³ Stars 75% - 84%

⁴ Stars 85% - 94%

⁵ Stars ≥95%

A. General Information

Name of Assessor(s)					
Title & organization of Assessor					
Name of laboratory being assessed					
Date, type and scope of last assessment?	Date	Туре	Score		
Internal					
External					
Did the last assessment include assessment of bacterial culture of wound samples?	Y/N				

B. Technical Information

W.A How many wound culture tests and molecular tests were performed last year^{4,5}?

W.A How many wound cut		Cult		,			cular	
	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
Hospital-acquired ⁶								
S. aureus								
S. pyogenes								
Enterococcus sp.								
Enterobacteriaceae								
P. aeruginosa								
Community-acquired ⁷								
S. aureus								
S. pyogenes								
Enterococcus sp.								
Enterobacteriaceae								
P. aeruginosa								
Unknown/referred ⁸								
S. aureus								
S. pyogenes								
Enterococcus sp.								
Enterobacteriaceae								
P. aeruginosa								
TOTAL ISOLATES								
TOTAL NUMBER OF WOUND								
TESTS PERFORMED								
TOTAL NUMBER OF WOUND								
CULTURES WITH NO PATHOGENS ISOLATED OR								
IDENTIFIED								

Q = Quarter

⁴ It is highly recommended that assessors obtain the necessary permission to review the laboratory data. However, if assessors are unable to review the laboratory data this question is NOT compulsory for completion of the assessment.

⁵ http://www.who.int/glass/en/ and other frequently isolated pathogens.

⁶ Hospital-acquired infections are defined as bacterial infections in hospitalized patients (i.e. pathogenic bacterial isolated from a sample collected more than 48 hours after admission).

⁷ Community-acquired infections are defined as ambulatory patients and hospitalized patients from which a sample was collected less than 48 hours after admission.

⁸ If the laboratory can't distinguish between hospital & community acquired infections, the number of organisms isolated should be recorded as "Unknown/referred".

W.B Are there any significant variations (> 20%) in the number of wound culture tests perfor	med o
organisms isolated or identified each quarter? If 'Yes', please explain ⁹	

⁹ It is highly recommended that assessors obtain the necessary permission to review the laboratory data. However, if assessors are unable to review the laboratory data this question is NOT compulsory for completion of the assessment.

Section 1: Documents & Records

All generic requirements apply, see SLIPTA Section 1. In addition, assessors should review the following:

SLIPT	91		N	Υ	Р	N	Comments	Score
A			A				Comments	000.0
1.5	W1.1	Does the laboratory have documentation covering the following processes? a) Production of Blood Agar, MacConkey Agar or other media for wound culture pathogen isolation?						
		b) Processing of wound samplesc) Detection, identification and AST of wound pathogens						2
		d) Reporting of wound culture and molecular test results e) Interlaboratory comparison or						
1.5	W1.2	proficiency testing (PT) f) Laboratory safety Are the documents						
		complete, in-date and witnessed by all staff performing wound culture and molecular tests ¹⁰ ?						2
1.5	W1.3	Are the following processes documented? a) Rejection criteria for wound samples?						
		b) A policy for reporting critical results?						
		c) Instructions for reporting wound culture tests with mixed bacterial growth?						3
		d) Instructions for referral of wound culture or molecular tests at the						

¹⁰ See ISO15189:2012 Clause 5.5.3 for minimum requirements for a technical Standard Operating Procedure (SOP).

SLIPT			N	Υ	Р	N	Comments	Score
A			Α					
		laboratory?						
	e)	Instructions for						
		handling samples						
		received after						
		hours?						
	f)	Instructions for						
		referral of bacterial						
		isolates for identification and						
		AST?						
	g)	Instructions on how						
	97	to perform AST						
		conversions for						
		automated, disk						
		diffusion, Etest /						
		Gradient and						
		microdilution AST?						
	h)	Turnaround time for						
		wound culture or						
	.,	molecular tests 11?						
	i)	Definition of rare /						
		unexpected AST results?						
	j)	Confirmatory tests						
	17	for unusual or						
		unexpected patient						
		AST results?						
Section 1: Do	ocumen	nts & Records Subtota						7

Section 2: Management Reviews

Section 3: Organization & Personnel

All generic requirements apply, see SLIPTA Section 3. In addition, assessors should review the following:

SLIPT	J		N	Υ	Р	N	Comments	Score
Α			Α					
3.6	W3.1	Is there evidence that						
		laboratory staff have been						
		trained in the following ¹² :						
		a) Processing of wound						
		samples for culture and						3
		molecular tests						
		b) Identification and AST						
		of wound pathogens						

 $^{^{\}rm 11}$ From sample collection to reporting.

¹² Review training records, competency assessment forms and duty rosters. Pay attention to date of training and scope of training compared with techniques being performed.

SLIPT A			N A	Υ	Р	N	Comments	Score
		c) Interpretation of wound culture and molecular test results						
		d) Reporting of wound culture and molecular test results						
		e) QC, EQA & PT for wound culture and molecular tests						
3.7	W3.2	f) Laboratory safety Is there evidence that						
3.7	W3.2	laboratory staff are following the procedures described in the laboratory documentation? ¹³ :						
		a) Processing of wound for culture and molecular tests						3
		b) Interpretation of wound culture test results						
		c) Identification and AST of wound pathogens						
		d) Reporting of wound culture test and molecular test results						
Section	3: Orga	nization & Personnel Subtota						6

Section 4: Client Management & Customer Service

All generic requirements apply, see SLIPTA Section 4. In addition, assessors should review the following:

SLIPT A		N A	Υ	Р	N	Comments	Score
4.1 W4	laboratory has provided clients information / instructions on wound sample collection, storage and transportation to the laboratory? Does the information / instructions include: a) Use of sterile techniques for collecting wound samples from sterile sites? b) Collection procedures						3
	for culture of anaerobic						

 $^{^{\}rm 13}$ Directly observe procedures being performed compared to the SOP.

SLIPT A			N A	Υ	Р	N	Comments	Score
		organisms?						
		c) Interpretation of						
		contaminated results?						
4.1	W4.2	Is there evidence that the						
		laboratory has provided						
		clients information /						2
		instructions on						
		interpretation of wound						
		culture results and AST?						
Section	4: Clier	nt Management & Customer S	Servic	e Sub	total			5

Section 5: Equipment

Section 6: Evaluation and Audits

Section 7: Purchasing & Inventory

All generic requirements apply, see SLIPTA Section 7. In addition, assessors should review the following:

SLIPT	J.		N	Υ	Р	N	Comments	Score
A			Α					
7.10	W7.1	Is all media for bacterial culture isolation, identification and AST stored correctly and in date (from date of manufacture media must be stored at 2-8 °C) ¹⁴ ?						2
		Blood Agar						
		 MacConkey agar 						
		 Mueller Hinton 						
		CNA agar						
Section	7: Purc	hasing & Inventory Subtot	al					2

¹⁴ According to manufacturer's requirements.

Section 8: Process Control

All generic requirements apply, see SLIPTA Section 8. In addition, assessors should review the following:

CLUDT	9.		NI.	V	_	NI	Commondo	Carre
SLIPT			N	Υ	Р	N	Comments	Score
A	OLIAL ITY	CONTROL	Α					
8.8	W8.1	CONTROL Does the laboratory				<u> </u>		
0.0	VV O. 1	perform QC testing on all						
		media before use ¹⁵ ?						
		Blood agar						
		Do QC records for blood						
		agar plates demonstrate						
		that they are checked for						
		their ability to support						
		growth of fastidious						
		organisms such as S.						
		pneumoniae?						
		Do QC records for blood						
		agar plates demonstrate						
		that they are checked for						
		their ability to show beta, alpha, and gamma						
		hemolysis?						
		MacConkey agar (MAC)						
		Do QC records for MAC						
		plates demonstrate that						
		they are checked for their						
		ability to suppress growth						3
		of Gram-positive organisms						3
		while allowing the growth						
		of Gram-negative						
		organisms?						
		Do QC records for MAC plates demonstrate that						
		they are checked for their						
		ability to allow visualization						
		of lactose fermentation?						
		Mueller Hinton Agar (MHA)			<u> </u>			
		Do QC records						
		demonstrate that MHA						
		plates are checked for their						
		ability to grow S. aureus &						
		E. coli?						
		CNA agar ¹⁶						
		Do QC records for CNA						
		agar plates demonstrate						
		that they are checked for their ability to suppress						
		growth of Gram-negative						
		organisms while allowing						
		organismo winic anowing				<u> </u>	1	

 $^{^{\}rm 15}\,\rm This$ includes in-house made or purchased from commercial sources.

 $^{^{\}rm 16}\,{\rm See}$ user guide for more information.

							sceptibility resumg of woun	
SLIPT			N	Υ	Р	N	Comments	Score
Α		the supervite of Overs	Α				l e	
		the growth of Gram-						
		positive organisms?						
		Do QC records						
		demonstrate that CNA agar						
		plates are checked for their						
		ability to grow S. pyogenes						
		& S. aureus?						
8.8	W8.2	Does the laboratory:						
		Perform sterility and						
		performance tests for						
		every batch of culture						
		media using certified						
		reference strains as						
		controls?						
		 Are reference strains 						
		sourced from an						2
		authorized supplier						
		(e.g. ATCC)?						
		 Are the reference 						
		strains stored, cultured						
		and sub-cultured in						
		accordance with the						
		specification from the						
		supplier?						
8.10	W8.3	Does the laboratory						
		determine the cause of						
		failed QC (root cause						
		analysis), perform						3
		corrective actions and						
		measure the effectiveness						
		thereof?						
WOUN	D CULTU	RE PROCEDURE ¹⁷						
8.7	W8.4	Are wound cultures plated						
		onto non-selective media						
		including (at least):						2
		 Blood Agar 						
		 MacConkey 						
8.7	W8.5	Are wound culture plates						
		incubated at 35-37 degrees						
		Celsius aerobically and						2
		anaerobically if applicable?						
8.7	W8.6	Does the laboratory report						
		wound cultures as						
		contaminated if they						
		contain organisms that						
		should be considered						2
		contaminants (e.g. <i>Bacillus</i>						
		sp., Coagulase-negative						
		Staphylococcus,						

 $^{^{\}rm 17}\,{\rm For}$ complete recommended procedure, see the User Guide.

SLIPT A			N A	Υ	Р	N	Comments	Score
		Corynebacterium sp.)?						
BACT	ERIAL ID 8	AST						
8.7	W8.7	Is the following testing performed for <i>S. aureus</i> identification: ¹⁸ • Catalase • Coagulase (slide or tube) • Mannitol Salt Agar (MSA) • Dnase						2
8.7	W8.8	Does S. aureus AST include the following antibiotics ¹⁹ : • Cefoxitin • Vancomycin			-			2
8.7	W8.9	Does the laboratory detect methicillin/nafcillin resistance in <i>S. aureus</i> using oxacillin disk?			-			2
8.7	W8.10	Is the following testing performed for Streptococcus sp. and Enterococcus sp. Identification: Bacitracin Pyrrolidonyl Arylamidase (PYR) Bile solubility Optochin S. pneumoniae latex						2
8.7	W8.11	Does Streptococcus sp. AST include the following antibiotics: Oxacillin ²⁰ Co-trimoxazole Ceftriaxone or cefotaxime						2
8.7	W8.12	Is the following testing performed to identify Gram negative bacilli: Oxidase Indole						2

¹⁸ If the laboratory performs penicillin AST, it is recommended that *S. aureus* isolates with penicillin zones sizes or MICs in the susceptible range are tested for B-lactamase production using the zone-edge test or a nitrocefin test before being reported as penicillin susceptible.

penicillin susceptible.

19 If oxacillin and cefoxitin results are discrepant for *S. aureus* (one is susceptible and one is resistant), the laboratory should repeat the testing. Note: oxacillin testing should always be tested by MIC (not disc diffusion). If the results remain discrepant, oxacillin should be reported as resistant.

 $^{^{20}}$ If the laboratory uses an oxacillin disk (1ug) to screen for penicillin resistance (Penicillin G or Benzylpenicillin, the IV formulation) in *S. pneumoniae* and the zone size < 20, then the laboratory must do an MIC method before reporting penicillin as resistant (CLSI recommendation). EUCAST recommends that if the zone size is < 20mm to do a MIC, if \geq 20 mm the result should be reported as susceptible.

SLIPT A			N A	Υ	Р	N	Comments	Score
	Mode	 Methyl Red Voges Proskauer Citrate Triple Sugar Iron or Kligler Iron Urease Motility 						
8.7	W8.13	Does the lab follow the latest CLSI /EUCAST guidelines for AST of Gram negative bacilli ²¹ ?						2
8.7	W8.14	Does the laboratory use Combination Disk Test or another equivalent method for Extended Spectrum Beta-Lactamase (ESBL) screening ²² ?						2
8.7	W8.15	Does the laboratory use Combination Disk Test or another equivalent method for carbapenemase screening?						2
INTERI	ABORAT	ORY COMPARISON, PT AND	EXTE	RNAL	. QUA	LITY	ASSURANCE (EQA)	
8.14	W8.16	Is the laboratory enrolled in an interlaboratory comparison or PT program for wound culture and molecular tests for organism identification, and AST?						2
8.14	W8.17	Did the laboratory pass the last 3 rounds of interlaboratory comparison or PT program testing?						2
8.14	W8.18	Does the laboratory receive onsite supervision visits as part of the EQA program for wound culture and molecular tests?						2
Section	า ช: Proce	ss Control Subtotal						38

²¹ https://www.clsi.org / www.eucast.org/) ²² J Clin Microbiol. 2013 Sep; 51(9): 2986–2990.

Section 9: Information Management

All generic requirements apply, see SLIPTA Section 9. In addition, assessors should review the following:

SLIPT A			N A	Υ	Р	N	Comments	Score
9.3	W9.1	Does the final report for wound culture list the organisms for which the specimen was and was not cultured ²³ ?						2
9.3	W9.2	Does the laboratory report alert organisms which include at least ²⁴ ? • Methicillin resistant S. aureus • Carbapenem resistant Enterobacteriaceae • ESBL producing organisms • Multidrug resistant Pseudomonas						2
Section	9: Infor	mation Management Subt	otal				I	4

Section 10: Identification of Non-conformities, Corrective and Preventive Actions

-

Section 11: Occurrence/Incident Management & Process Improvement

All generic requirements apply, see SLIPTA Section 11. In addition, assessors should review the following:

SLIPT A			N A	Y	Р	N	Comments	Score
11.4 / 11.5	P11.1	Are the following performance indicators collected ²⁵ ?						
		 Number of wound culture and molecular tests performed (disaggregated by type) 						3
		 Hospital- acquired²⁶ 						

²³ The laboratory should inform the clinician on the report what organisms were excluded during the culture process. This may be either by choice of media or incubation conditions (e.g. anaerobic organisms). Assessors should review a number of laboratory reports to determine how results are reported. Procedures should be consistent with the laboratory's SOPs.

²⁴ Alert organisms are organisms with significant public health threat and / or organisms that are notifiable.

²⁵ It may not be possible for laboratories to distinguish between community and hospital acquired infection if this is not collected on the laboratory requisition form.

²⁶ Hospital-acquired infections are defined as bacterial infections in hospitalized patients (i.e. pathogenic bacterial isolated from a sample collected more than 48 hours after admission).

SLIPT		N	Υ	Р	N	Comments	Score
Α		Α					
	o Community- acquired ²⁷						
	 Unknown/ referred²⁸ 						
	 Number of wound culture and molecular tests where pathogens were isolated (disaggregated by 						
	type)						
	S. aureusS. pyogenes						
	Enterococcus sp.						
	o Enterobacteriac eae						
	o P. aeruginosa						
	Total number of wound cultures with no						
	pathogens Isolated or identified						
	Wound culture and molecular test TAT ²⁹						
	(disaggregated by in- patient & out-patient and by type)						
Section 11: Occu	urrence/Incident Manager	nent 8	⊾ & Pro	cess	mpro	vement Subtotal	3

Section 12: Facilities and Biosafety

The Antimicrobial Resistance (AMR) Laboratory Quality Scorecard was developed in collaboration with and support from Becton Dickinson and Company (BD)

²⁷ Community-acquired infections are defined as ambulatory patients and hospitalized patients from which a sample was collected less than 48 hours after admission.

²⁸ If the laboratory can't distinguish between hospital & community acquired infections, the number of organisms isolated should be recorded as "Unknown/referred".

²⁹ From sample collection to reporting.





Africa Centres for Disease Control and Prevention (Africa CDC), African Union Commission Roosevelt Street W21 K19, Addis Ababa, Ethiopia









